Volume Spike Investor

Bank of America Corporation (NYSE: BAC) is almost always one of the most active call options stocks out there.  But today we are seeing a flurry of trading activity based upon last night’s announcement that it is repaying the full TARP amount.  This first list is the DEC-2009 CALLS and we followed it with DEC-2009 [...]

Huntsman Corporation (NYSE: HUN) is seeing a surge in options activity.  There have been 30,698 calls traded, 15X average, and implied volatility is spiking 44% on rumors that Dupont (NYSE: DD) is looking at a possible $18 offer for shares of the company.  The action has been  extremely bullish with block buyers in calls at [...]

Geron Corporation (NASDAQ: GERN), StemCells Inc. (NASDAQ: STEM), and Opexa Therapeutics, Inc. (NASDAQ: OPXA) are all playing give-back this morning on the heels of monster gains yesterday due to the National Institutes of Health approving new embryonic stem cell lines.
At 8:39 AM EST we have GERN down 2.9% at $6.02 on 80,000 shares, STEM down [...]

Ambac Financial Group Inc. (NYSE: ABK) is soaring this morning in pre-market trading on an S&P upgrade.  The rating was raised to a still dismal “CC.”  Still, anything is better than nothing, particularly when we listed this one as a brand which is likely to disappear in 2010.  Shares are up 18% at $0.96 on [...]

DryShips, Inc. (NASDAQ: DRYS) is strong this morning after the Greek shipper was started in analyst coverage with a “Buy” rating at Deutsche Bank.  At 8:21 AM EST we have shares trading up 4.4% at $6.58 on over 440,000 shares of stock.  Average volume here is still 25 million.  After the crazy moves seen on [...]

Human Genome Sciences, Inc. (NASDAQ: HGSI) has raised its stock offering due to strong demand.  The company sold 15,500,000 new shares of common stock at $26.75 per share after a $27.46 closing bell price Wednesday. The size of the offering was increased from 12,500,000 shares.  Net proceeds from the offering are now estimated at approximately [...]

Targacept, Inc. (NASDAQ: TRGT) is indicated higher in pre-market trading, but on thinner volume than some might expect.  The company has formed a global collaboration and license agreement with AstraZeneca (AZN) for late-stage investigational product TC-5214 for the treatment of major pepressive disorder.  The company will recive $1.24 billion over time in the pact, which [...]